Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
3 Total results for product and free and sample content found
Scrip
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
Scrip
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Topic Obesity Clinical Trials
Datamonitor Healthcare
The US obesity market is expected to increase in value from $533m in 2016 to $1.2bn in 2026, at a compound annual growth rate of 8.0%. Growth will be driven by increased use of branded pharmacological therapies to treat obesity, as well as the rising incidence of the disease.
Topic Obesity Research wire
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
